Response rates ranging from 10–25% have been observed in Phase II studies in EGFR-mutated and ALK-rearranged NSCLC and HER2+ breast cancer resistant to standard treatment [144,145]. This evidence concerns the gene ALK and non-small cell lung carcinoma.